Eterna Financial Statements From 2010 to 2024

Stocks . USA . 
Stock . Eterna Therapeutics
ERNA Stock  USD 0.29  0.03  9.38%   
Eterna Therapeutics financial statements provide useful quarterly and yearly information to potential Eterna Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Eterna Therapeutics financial statements helps investors assess Eterna Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Eterna Therapeutics' valuation are summarized below:
Market Capitalization
16.6 M
Enterprise Value Revenue
73.8685
Revenue
162 K
Earnings Share
(8.31)
Revenue Per Share
0.03
We have found one hundred twenty available fundamental signals for Eterna Therapeutics, which can be analyzed and compared to other ratios and to its rivals. All investors should make sure to verify all of Eterna Therapeutics prevailing market performance against the performance between 2010 and 2024 to make sure the company can sustain itself down the road. The current year's Market Cap is expected to grow to about 170.6 M. The current year's Enterprise Value is expected to grow to about 157.2 M

Eterna Therapeutics Total Revenue

64,600

Check Eterna Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Eterna Therapeutics' main balance sheet or income statement drivers, such as Total Revenue of 64.6 K, Other Operating Expenses of 20 M or Total Operating Expenses of 19.3 M, as well as many indicators such as Price To Sales Ratio of 133, Dividend Yield of 0.0018 or PTB Ratio of 4.42. Eterna financial statements analysis is a perfect complement when working with Eterna Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Eterna Therapeutics Correlation against competitors.
For information on how to trade Eterna Stock refer to our How to Trade Eterna Stock guide.

Eterna Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets51.6 M49.1 M22.4 M
Slightly volatile
Other Current Liabilities837.9 K882 K2.2 M
Slightly volatile
Total Current Liabilities5.9 M6.6 M5.7 M
Very volatile
Total Stockholder Equity2.1 M2.2 M7.3 M
Slightly volatile
Non Current Assets Total41.5 M39.5 M13 M
Slightly volatile
Non Currrent Assets Other114 K120 K2.6 M
Slightly volatile
Common Stock Shares Outstanding5 M5.3 M30.6 M
Slightly volatile
Liabilities And Stockholders Equity51.6 M49.1 M22.4 M
Slightly volatile
Non Current Liabilities Total42.3 M40.3 M9.4 M
Slightly volatile
Other Current Assets2.3 M1.6 M3.4 M
Slightly volatile
Total Liabilities49.2 M46.9 M15.2 M
Slightly volatile
Total Current Assets9.8 M9.6 M9.4 M
Pretty Stable
Short and Long Term Debt Total43.9 M41.8 M9 M
Slightly volatile
Property Plant And Equipment Net34.9 M33.3 M7.6 M
Slightly volatile
Current Deferred Revenue207.6 K218.5 K959.5 K
Pretty Stable
Accounts Payable764.4 K1.1 M767.6 K
Slightly volatile
Cash6.1 M7.6 M5.9 M
Slightly volatile
Cash And Short Term Investments6.1 M7.6 M5.9 M
Slightly volatile
Net Receivables678.2 K425 K886.5 K
Slightly volatile
Good Will1.4 M2.4 M1.3 M
Slightly volatile
Short Term Debt4.7 M4.4 M2 M
Slightly volatile
Intangible Assets8.3 M7.9 M3.7 M
Slightly volatile
Common Stock25.6 K27 K1.9 M
Pretty Stable
Other Liabilities2 M1.9 M953.8 K
Slightly volatile
Net Tangible Assets12.1 M11.6 M9.7 M
Slightly volatile
Other Assets4.2 M4.7 M6.3 M
Slightly volatile
Deferred Long Term Liabilities5.1 M5.4 M6.5 M
Slightly volatile
Property Plant Equipment1.7 M1.5 M776.9 K
Slightly volatile
Long Term Debt7.1 M6.8 M1.2 M
Slightly volatile
Capital Lease Obligations36.8 M35.1 M6.7 M
Slightly volatile
Net Invested Capital10.7 M9 M8.9 M
Slightly volatile
Property Plant And Equipment Gross35.1 M33.4 M6.9 M
Slightly volatile
Short and Long Term Debt1.3 M2 M836.7 K
Slightly volatile
Capital Stock23.9 K25.2 K18.9 M
Slightly volatile
Non Current Liabilities Other181.4 K191 K1.4 M
Pretty Stable

Eterna Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Other Operating Expenses20 M21.2 M24.5 M
Slightly volatile
Total Operating Expenses19.3 M20.7 M23.6 M
Slightly volatile
Depreciation And Amortization1.1 M1.1 M5.3 M
Slightly volatile
Interest Expense644.7 K614 K267.5 K
Slightly volatile
Cost Of Revenue224.2 K236 K985.7 K
Very volatile
Research Development7.3 M5.9 M2.7 M
Slightly volatile
Selling General Administrative13.6 M14.6 M6.4 M
Slightly volatile
Reconciled Depreciation490.1 K728 K216.8 K
Slightly volatile
Selling And Marketing Expenses800900980
Slightly volatile

Eterna Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation1.2 M1.2 M33.6 M
Slightly volatile
Depreciation1.1 M1.1 M264.1 M
Slightly volatile
Begin Period Cash Flow16.3 M15.5 M6.3 M
Slightly volatile
Change To Inventory312.4 K301.3 K318.8 K
Pretty Stable
Issuance Of Capital Stock7.6 M8 M9.7 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio13312745.7916
Slightly volatile
Dividend Yield0.00180.00170.0013
Pretty Stable
PTB Ratio4.424.28364.8793
Pretty Stable
Days Sales Outstanding2.2 K2.1 K747
Slightly volatile
Book Value Per Share0.40.420258.5087
Slightly volatile
Stock Based Compensation To Revenue14.6116.4417.8994
Slightly volatile
Capex To Depreciation0.01610.01690.4243
Slightly volatile
PB Ratio4.424.28364.8793
Pretty Stable
EV To Sales609580209
Slightly volatile
Payables Turnover0.210.221230.9237
Slightly volatile
Sales General And Administrative To Revenue172193210
Slightly volatile
Research And Ddevelopement To Revenue82.2778.3528.1235
Slightly volatile
Capex To Revenue0.260.250.1319
Slightly volatile
Cash Per Share1.351.425546.5074
Slightly volatile
Days Payables Outstanding1.7 K1.7 K722
Slightly volatile
Intangibles To Total Assets0.03950.04160.1067
Pretty Stable
Current Ratio1.411.46041.7447
Very volatile
Receivables Turnover0.170.1816.7826
Slightly volatile
Graham Number5.96.209287
Slightly volatile
Shareholders Equity Per Share0.40.420258.5087
Slightly volatile
Debt To Equity4.234.02551.678
Very volatile
Capex Per Share0.00340.003619.6013
Slightly volatile
Revenue Per Share0.0140.0147309
Slightly volatile
Interest Debt Per Share1.721.807198.7531
Slightly volatile
Debt To Assets0.290.1830.323
Slightly volatile
Operating Cycle2.2 K2.1 K783
Slightly volatile
Price Book Value Ratio4.424.28364.8793
Pretty Stable
Days Of Payables Outstanding1.7 K1.7 K722
Slightly volatile
Company Equity Multiplier23.122.00276.1468
Slightly volatile
Long Term Debt To Capitalization0.790.75210.4538
Slightly volatile
Total Debt To Capitalization0.470.8010.5121
Slightly volatile
Debt Equity Ratio4.234.02551.678
Very volatile
Quick Ratio1.271.46041.6294
Very volatile
Cash Ratio0.961.15240.9915
Slightly volatile
Cash Conversion Cycle596568242
Slightly volatile
Days Of Sales Outstanding2.2 K2.1 K747
Slightly volatile
Price To Book Ratio4.424.28364.8793
Pretty Stable
Fixed Asset Turnover0.00220.00243.9076
Slightly volatile
Debt Ratio0.290.1830.323
Slightly volatile
Price Sales Ratio13312745.7916
Slightly volatile
Asset Turnover0.00150.00160.947
Slightly volatile
Price Fair Value4.424.28364.8793
Pretty Stable

Eterna Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap170.6 M162.5 M59.6 M
Slightly volatile
Enterprise Value157.2 M149.7 M57.3 M
Slightly volatile

Eterna Fundamental Market Drivers

Cash And Short Term Investments7.6 M

Eterna Upcoming Events

18th of March 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View

About Eterna Therapeutics Financial Statements

Eterna Therapeutics stakeholders use historical fundamental indicators, such as Eterna Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Although Eterna Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Eterna Therapeutics' assets and liabilities are reflected in the revenues and expenses on Eterna Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Eterna Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue218.5 K207.6 K
Total Revenue68 K64.6 K
Cost Of Revenue236 K224.2 K
Stock Based Compensation To Revenue 16.44  14.61 
Sales General And Administrative To Revenue 193.05  171.60 
Research And Ddevelopement To Revenue 78.35  82.27 
Capex To Revenue 0.25  0.26 
Revenue Per Share 0.01  0.01 
Ebit Per Revenue(357.43)(339.56)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
CCitigroup
GMGeneral Motors
FFord Motor
When determining whether Eterna Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Eterna Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Eterna Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Eterna Therapeutics Stock:
How To Invest In Eterna
Details
Is Eterna Stock a good investment?
Details
What is Eterna Therapeutics' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Eterna Therapeutics Correlation against competitors.
For information on how to trade Eterna Stock refer to our How to Trade Eterna Stock guide.
You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eterna Therapeutics. If investors know Eterna will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eterna Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(8.31)
Revenue Per Share
0.03
Return On Assets
(0.29)
Return On Equity
(11.54)
The market value of Eterna Therapeutics is measured differently than its book value, which is the value of Eterna that is recorded on the company's balance sheet. Investors also form their own opinion of Eterna Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Eterna Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eterna Therapeutics' market value can be influenced by many factors that don't directly affect Eterna Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Please note, there is a significant difference between Eterna Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Eterna Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eterna Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY